SOURCE: Herborium Group, Inc.

Herborium Group, Inc.

January 13, 2011 10:10 ET

Herborium Group Developing U.K. Co-Marketing Campaign

SADDLE BROOK, NJ--(Marketwire - January 13, 2011) - Herborium Group, Inc., (PINKSHEETS: HBRM), a Botanical Therapeutics™ company, today announced the development of a co-marketing campaign with its largest distributor, Mankind Direct, LTD., to increase sales and market share of AcnEase® (, Herborium's proprietary, botanically based acne and rosacea treatment, in the United Kingdom (U.K.).

To date in the U.K., Herborium has recorded AcnEase sales of over $1M dollars, with Mankind responsible for over 50% of those sales. A leading direct marketing provider of upscale personal care products, Mankind is establishing a retail presence in a number of high-end British stores. Herborium has an upcoming editorial in the National Association of Primary Care Review read by nearly 40,000 U.K. general practitioners and dermatologists. The co-marketing will involve joint advertising, public relations and viral and social marketing campaigns.

"We are truly excited about increasing sales of AcnEase in the U.K.'s robust acne and rosacea market, which is expected to grow 12.8% in 2011. The projected world market for systemic acne products is $2.7 Billion," commented Dr. Agnes P. Olszewski, Herborium Group's President and CEO. 

Herborium's margin in the U.K. and European Union (E.U.) is very advantageous due to growing demand for natural medicines and the favorable currency exchange rate.

"While we expect this marketing effort to bring an additional $500,000 in revenues, it is also advances execution of our 'Road-to-Market' Strategy calling for revenue projections of $7.5 Million, with a goal to capture 1% of the global natural and alternative treatments market," Olszewski concluded. 

About Herborium Group, Inc.
Herborium Group, Inc., a Botanical Therapeutics® company, develops, licenses and markets proprietary, botanical based medicines to consumers and healthcare professionals. The Company uses clinical validation to establish and maintain a differential advantage. For more information, please visit

One of our most important responsibilities is to communicate with shareholders in an open and direct manner. Comments are based on current management expectations, and are considered "forward-looking statements," generally preceded by words such as "plans," "expects," "believes," "anticipates," or "intends." We cannot promise future returns. Our statements reflect our best judgment at the time, and we disclaim any obligation to update or alter forward-looking statements as the result of new information or future events. We urge investors to review the risks contained within our filings with the OTC Markets.  

Contact Information

  • Investor & Media Relations:
    Steve Haag
    (832) 577-2380